China's Jiangsu Nhwa Licenses Epilepsy Drug From Israel's D-Pharm
This article was originally published in PharmAsia News
Executive Summary
D-Pharm of Israel said it has licensed its DP-VPA (valproate) for treating epilepsy to China's Jiangsu Nhwa Pharmaceutical in China